Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Cancer Chemother Pharmacol ; 82(1): 165-170, 2018 07.
Artículo en Inglés | MEDLINE | ID: mdl-29869680

RESUMEN

BACKGROUND: Chemotherapy for breast cancer is associated with a high risk of neutropenia. Pegfilgrastim reduces the risk of neutropenic fever but commonly causes bone pain. OBJECTIVE: Evaluate whether a reduced dose of pegfilgrastim (3 mg) reduced the frequency of bone pain without compromising efficacy. METHODS: Records reviewed from breast cancer patients who received at least one 3 mg dose of pegfilgrastim, white blood count (WBC), and absolute granulocyte counts (AGC) were collected. Musculoskeletal pain scale was collected at each visit. RESULTS: 265 treatments from 36 women were analyzed. There was no difference in post-treatment AGC between 3 versus 6 mg. Leukocytosis (WBC > 20,000 cells/cu mm) was more likely for those treated with 6 mg (chi-square 5.265, p = 0.0215). There was higher change in bone pain in patients who received 6 mg doses compared to none or 3 mg. LIMITATIONS: In this retrospective, non-randomized study, we found the majority of patients received the reduced 3 mg dose after intolerance to the 6 mg dose. It is unknown if smaller or larger doses than 3 mg would achieve similar results or whether 3 mg dose would be effective as an initial therapy or for patients receiving different chemotherapy regimens. Pain is observed despite premedication with naproxen and/or loratidine. CONCLUSION: Reduced dose of pegfilgrastim 3 mg was less likely to cause bone pain. The reduced dose was not associated with a significant difference in post-treatment AGC or rate of serious infection.


Asunto(s)
Filgrastim/administración & dosificación , Filgrastim/efectos adversos , Dolor Musculoesquelético/inducido químicamente , Polietilenglicoles/administración & dosificación , Polietilenglicoles/efectos adversos , Adulto , Anciano , Anciano de 80 o más Años , Relación Dosis-Respuesta a Droga , Neutropenia Febril/inducido químicamente , Neutropenia Febril/prevención & control , Femenino , Humanos , Persona de Mediana Edad , Dolor Musculoesquelético/sangre , Dolor Musculoesquelético/prevención & control , Estudios Retrospectivos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA